24.70
-1.20%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Stratec Se
Its shares trade on XETRA under the ticker SBS.DE. It has been listed since 25 August 1998. In the fiscal year to 31 December 2025, it reported revenue of €250.9m and a net loss of €242,000. At that date it held total assets of €443.4m and shareholders' equity of €237.3m.
STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. The company is headquartered in Birkenfeld, Baden-Wuerttemberg. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 25 Aug 1998
- Employees
- 1,292
- Website
- stratec.com ↗
Leadership
Pay as last reported
- Prof. Dr. Georg HeniIndependent Chairman of the Supervisory Board, since 2022€96,000
- Mr. Marcus WolfingerChairman of the Management Board, Chief Executive Officer€900,000
- Dr. Frank HillerIndependent Deputy Chairman of the Supervisory Board, since 2019€76,000
- Mr. Oliver AlbrechtInterim Chief Financial Officer, Member of the Management Board
- Dr. Georg BauerDirector - Sales, Member of the Management Board€451,000
- Dr. Claus VielsackMember of the Management Board, Director - Product Development€653,000
- Dr. Patricia GellerIndependent Member of the Supervisory Board€56,000
- Dr. Rolf VornhagenIndependent Member of the Supervisory Board€51,000
- Mr. Jan KeppelerHead of Investor Relations, Sustainability and Corporate Communications, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 98
- Social
- 99
- Governance
- 66
- Direct emissions (scope 1)
- 639.1 t
- Energy emissions (scope 2)
- 1,376.7 t
- Value chain emissions (scope 3)
- 9,303.6 t
- Women in the workforce
- 36.1%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Stratec SE holds a dominant position in the market, offering unique and innovative products/services that have gained significant traction among customers.
- The company possesses strong technological expertise, allowing it to develop cutting-edge solutions that provide a competitive edge over rivals.
- Stratec SE boasts an efficient supply chain management system, ensuring timely delivery of products to customers while minimizing costs.
- The company invests heavily in research and development, continuously enhancing its product portfolio and offering innovative solutions to meet market demands.
Weaknesses
- Stratec SE relies heavily on a few key customers for a significant portion of its revenue, making it vulnerable to potential loss if these customers switch to competitors.
- The company's operations are primarily focused in specific geographic regions, limiting its exposure to global markets and potential opportunities.
- Stratec SE's product portfolio is relatively narrow, which could limit its ability to cater to diverse customer requirements and adapt to changing market dynamics.
Opportunities
- The global medical devices market is experiencing significant growth, presenting Stratec SE with opportunities to expand its customer base and increase revenues.
- Advancements in technologies like artificial intelligence and Internet of Things offer Stratec SE the chance to develop innovative solutions and gain a competitive edge in the market.
- The company can explore untapped markets and expand its operations internationally, diversifying its customer base and reducing dependency on specific regions or customers.
Threats
- The medical devices market is highly competitive, with numerous players vying for market share, which could potentially erode Stratec SE's market position and profitability.
- The industry is subject to stringent regulations and compliance requirements, and any changes in regulations could pose challenges for Stratec SE in terms of product development and market access.
- Rapid technological advancements may render Stratec SE's existing products/services obsolete if the company fails to adapt and innovate accordingly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.